Development of visual acuity under hyperbaric oxygen treatment (HBO) in non arteritic retinal branch artery occlusion.

Autor: Schmidt I; Department of Ophthalmology, University Hospital RWTH Aachen, Aachen, Germany. ischmidt@ukaachen.de., Walter P; Department of Ophthalmology, University Hospital RWTH Aachen, Aachen, Germany., Siekmann U; Department of Anesthesiology, University Hospital RWTH Aachen, Aachen, Germany., Plange N; Department of Ophthalmology, University Hospital RWTH Aachen, Aachen, Germany., Koutsonas A; Department of Ophthalmology, University Hospital RWTH Aachen, Aachen, Germany., Mazinani BE; Department of Ophthalmology, University Hospital RWTH Aachen, Aachen, Germany., Kuerten D; Department of Ophthalmology, University Hospital RWTH Aachen, Aachen, Germany.
Jazyk: angličtina
Zdroj: Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie [Graefes Arch Clin Exp Ophthalmol] 2020 Feb; Vol. 258 (2), pp. 303-310. Date of Electronic Publication: 2019 Dec 20.
DOI: 10.1007/s00417-019-04568-9
Abstrakt: Purpose: Nonperfusion of retinal tissue due to arterial occlusion leads inevitably to mostly irreversible retinal damage. Until today no evidence-based treatment exists. Inhalation of 100% oxygen at high atmospheric pressure causes an increased solubility of oxygen in the blood that helps the retinal tissue to survive through diffusion in case of an artery occlusion till vascular recanalization occurs. Hence the purpose of this study is to compare the visual outcome in patients with retinal branch artery obstruction treated with hyperbaric oxygen versus patients treated with hemodilution only.
Methods: Non-randomized, monocentric, retrospective study. Patients with diagnosis of non-arteritic retinal branch artery occlusion (BRAO) treated with hyperbaric oxygen therapy between 1997 and 2017. Exclusion criteria were central retinal artery occlusion, presence of a cilioretinal artery and arteritic cases. The control group was matched based on visual acuity (VA) at admission, age, and delay between symptoms and beginning of clinical care.
Results: The control group and the matching oxygen group contained 14 patients each. Initial VA in the matched HBO group was 0.18 ± 0.19 and 0.23 ± 0.19 in the control group (p = 0.57). Final VA at discharge was 0.69 ± 0.29 in the matched oxygen group and 0.32 ± 0.23 in the control group (p = 0.0009). HBO-treated patients had a significant visual increase compared with the control group. The most common comorbidities were arterial hypertension and vascular sclerosis.
Conclusion: HBO treatment appears to have a beneficial effect on visual outcome in patients with retinal branch artery occlusion. HBO treatment could be a rescue therapy at an early stage of BRAO, especially to bridge the time of a potential reperfusion. However, further, prospective, randomized clinical trials are required to verify this assumption.
Databáze: MEDLINE
Externí odkaz: